Teneligliptin
Tenepla, Tenebis, Tenglip, Tenelip, Teniglip, Teneza
DPP-4 Inhibitor (Dipeptidyl Peptidase-4 Inhibitor)
Teneligliptin is an oral antidiabetic medication belonging to the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, also known as gliptins. It works by increasing incretin hormone activity, which enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner. Teneligliptin helps achieve better glycemic control without causing significant hypoglycemia or weight gain. It is used as monotherapy or in combination with other oral agents such as metformin, sulfonylureas, or SGLT2 inhibitors in the management of Type 2 Diabetes Mellitus (T2DM). Teneligliptin is notable for its long half-life (~24 hours), allowing once-daily dosing.
Type 2 Diabetes Mellitus (T2DM) As monotherapy, when diet and exercise alone are insufficient. As add-on therapy with: Metformin Sulfonylureas (e.g., Glimepiride, Gliclazide) SGLT2 inhibitors (e.g., Dapagliflozin) Thiazolidinediones (e.g., Pioglitazone) Insulin (for combination therapy)
Type 1 Diabetes Mellitus Diabetic ketoacidosis (DKA) Severe hepatic impairment Known hypersensitivity to Teneligliptin or other DPP-4 inhibitors
Adults: 20 mg orally once daily (with or without food) Maximum dose: 40 mg once daily (in select patients with inadequate control) Renal Impairment: Mild to moderate → no adjustment Severe → use with caution, consider dose reduction Hepatic Impairment: Mild → generally safe Moderate to severe → not recommended
Long-term glycemic control in Type 2 Diabetes Mellitus Useful in patients at risk of hypoglycemia or weight gain with other drugs Often combined with metformin or SGLT2 inhibitors for enhanced effect
⚠️ Common: Headache Nasopharyngitis (sore throat, mild cold) Constipation or mild gastrointestinal discomfort Dizziness or fatigue ⚠️ Less Common / Rare: Hypoglycemia (mainly when used with insulin or sulfonylureas) Elevated liver enzymes (rare) Hypersensitivity reactions (rash, pruritus) Pancreatitis (very rare)
Avoid
Avoid
Monitor liver function tests periodically. Use cautiously in patients with renal or hepatic dysfunction. Avoid alcohol and high-sugar diets. Watch for signs of pancreatitis (abdominal pain, nausea). May be safely combined with metformin for dual therapy.
Teneligliptin inhibits the DPP-4 enzyme, which is responsible for the degradation of incretin hormones — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). By inhibiting DPP-4, Teneligliptin: Increases circulating incretin levels Enhances insulin secretion in response to glucose Suppresses glucagon secretion after meals Improves overall glycemic control (reduces both fasting and postprandial glucose levels) These effects are glucose-dependent, meaning Teneligliptin rarely causes hypoglycemia when used alone.
Copyright © 2026 MediWise
